Coactivation of GABA<sub>A</sub> and GABA<sub>B</sub> Receptor Results in Neuroprotection During In Vitro Ischemia

Cinzia Costa, MD; Giorgia Leone, MD; Emilia Saulle, MD; Francesco Pisani, MD; Giorgio Bernardi, MD; Paolo Calabresi, MD

Background and Purpose—The possible neuroprotective effect of endogenous γ-aminobutyric acid (GABA) on the irreversible electrophysiological changes induced by in vitro ischemia on striatal neurons was investigated. In particular, the aim of the study was the characterization of the neuroprotective action of 2 antiepileptic drugs increasing GABAergic transmission such as tiagabine, a GABA transporter inhibitor, and vigabatrin, an irreversible inhibitor of GABA transaminase.

Methods—Extracellular field potential recordings were obtained from rat corticostriatal slice preparations. In vitro ischemia was delivered by switching to an artificial cerebrospinal fluid solution in which glucose was omitted and oxygen was replaced with N<sub>2</sub>.

Results—An irreversible loss of the field potentials recorded from striatal neurons was observed after 10 minutes of ischemia in control solution. Conversely, tiagabine and vigabatrin partially prevented the ischemia-induced field potential loss. Surprisingly, both GABA<sub>A</sub> and GABA<sub>B</sub> receptor antagonists blocked these effects. Accordingly, neuroprotection could be obtained only when GABA<sub>A</sub> and GABA<sub>B</sub> receptor agonists were coapplied, but not when a single agonist was given in isolation.

Conclusions—Antiepileptic drugs targeting GABAergic transmission can exert neuroprotective effects against ischemia by increasing endogenous GABA levels and via the activation of both GABA<sub>A</sub> and GABA<sub>B</sub> receptors. (Stroke. 2004;35:596-600.)

Key Words: anticonvulsants • corpus striatum • electrophysiology • ischemia • receptors, GABA
Materials and Methods

Preparation and maintenance of rat corticostriatal slices have been previously described. Briefly, corticostriatal coronal slices were prepared from 2- to 3-month-old Wistar rats (thickness, 270 to 300 μm). All the experiments were conducted in conformity with the European Communities Council Directive of November 1986 (86/609/ECC). Slices were kept in artificial cerebrospinal fluid, whose composition was as follows (in mmol/L): 126 NaCl, 2.5 KCl, 1.2 MgCl₂, 1.2 NaH₂PO₄, 2.4 CaCl₂, 11 glucose, and 25 NaHCO₃, with 2 mol/L NaCl. An Axoclamp 2B amplifier (Axon Instruments) was used for extracellular recordings. The field potential amplitude was defined as the average of the amplitude from the peak of the early positivity to the peak negativity and the amplitude from the peak negativity to peak late positivity. Quantitative data on modifications induced by ischemia are expressed as a percentage of the control values, the latter representing the mean of responses recorded during a stable period (15 to 20 minutes) before the ischemic phase. Tracings were displayed on a digital oscilloscope (Classic 6000, Gould) and digitally stored.

For data presented as mean±SEM, statistical analysis was performed with the use of Student’s t test. The significance level was established at P<0.05.

Drugs were applied by dissolving them to the desired final concentration in saline solution. Tiagabine was from Sanofi-Synthelabo; vigabatrin was from Camillo Corvi; GABA_A, muscimol, and CGP 46381 were from Tocris-Cookson; and bicuculline was from Sigma.

Results

Neuroprotective Effect of Tiagabine and Vigabatrin During In Vitro Ischemia

Excitatory glutamatergic field potentials were recorded from the striatum of corticostriatal rat slices. In electrophysiological experiments (n=97), the white matter between cortex and striatum was stimulated to obtain field potentials of 1.2±0.3 mV in amplitude and 2±0.5 ms in duration. Stimuli (0.03±0.01 ms and 1 to 5 V) were delivered at a frequency of 0.1 Hz to monitor the time course of field potential amplitude. After 10 to 15 minutes of stable baseline recording, ischemia was applied for 10 minutes. This treatment progressively reduced the amplitude of the field potential, which was completely suppressed in approximately 5 minutes. After the washout of the ischemic medium, the field potential did not recover (P<0.001; n=20) (Figure 1A).

The application of 30 μmol/L tiagabine for 10 minutes did not alter per se the amplitude of the field potential. However, in the presence of tiagabine, the field potential partially recovered 10 to 20 minutes after the washout of the ischemic solution (Figure 1A), reaching 41±5% of the preischemic value (P<0.01 compared with control; n=12). Similar results were obtained by the application of 10 μmol/L vigabatrin, which had a neuroprotective effect on field potential even stronger than tiagabine (Figure 2A). In fact, in the presence of vigabatrin, the field potential recovery after in vitro ischemia was approximately 53±6% of the preischemic value (P<0.01 compared with control; n=12).

The efficacy of tiagabine increased from 10 to 30 μmol/L (P<0.01, n=5; P<0.01, n=12, respectively), whereas at lower (3 μmol/L) or higher (100 and 300 μmol/L) doses it had no significant effect on posts ischemic field potential recovery (P>0.05; n=4 for all) (Figure 1C). Similarly, vigabatrin had a maximal neuroprotective effect at 10 μmol/L (P<0.01; n=12), while it decreased at 30 μmol/L (P<0.05, n=7). Doses of 3 or 100 μmol/L had no significant effects on posts ischemic field potential recovery (P>0.05; n=4 for both) (Figure 2C).

Coactivation of GABA_A and GABA_B Receptor Is Required for Neuroprotective Effects Against In Vitro Ischemia

Both tiagabine and vigabatrin are known to act on synaptic GABA levels with different mechanisms. Thus, to verify whether their neuroprotective effects were mediated by an
increased GABA_A and/or GABA_B receptor function, we applied these drugs in combination with either bicuculline (3 to 10 μmol/L), a GABA_A receptor antagonist, or CGP 46381 (100 μmol/L), a GABA_B receptor antagonist. Surprisingly, the neuroprotective effects of both tiagabine (30 μmol/L) (Figure 1D) and vigabatrin (100 μmol/L) (Figure 2D) were largely reduced by both of these GABA receptor antagonists. In particular, the tiagabine-mediated field potential recovery was reduced to 4 ± 1.5% and 3.5 ± 1.5% of preischemic values by bicuculline and CGP 46381, respectively (P < 0.01 compared with tiagabine alone; n = 4 for both), while the vigabatrin-mediated field potential recovery was reduced to 5 ± 1.5% and 4.5 ± 1.5% (P < 0.01 compared with vigabatrin alone; n = 4 for both).

**Exogenous GABA and Direct GABAergic Agonist Mimic the Neuroprotective Effect of Tiagabine and Vigabatrin**

We also measured the possible neuroprotective action caused by exogenous GABA. In the presence of GABA (100 μmol/L), the field potential partially recovered 10 to 20 minutes after the washout of the ischemic solution (Figure 3A), reaching 36 ± 3% of the preischemic value (P < 0.01 compared with control; n = 5).

However, while GABA was protective at 100 μmol/L (P < 0.01, n = 5), lower (30 and 50 μmol/L) or higher (200 and 300 μmol/L) doses of this transmitter had no significant effect on postischemic field potential recovery (P > 0.05; n = 4 for all) (Figure 3B).
Interestingly, the neuroprotective effect of 100 μmol/L GABA (Figure 3C) was largely reduced by either bicuculline (3 to 10 μmol/L) or CGP (100 μmol/L). In particular, the GABA-mediated field potential recovery was reduced to 5±3% and 5±2.5% of preischemic values by bicuculline and CGP 46381, respectively (P<0.01 compared with GABA alone; n=4 for both).

Thus, our hypothesis was that the neuroprotective effect of tiagabine and vigabatrin is mediated by the activation of both GABA A and GABA B receptors. To further investigate the receptor mechanisms of the neuroprotective action, we used 2 GABA agonists: muscimol (1 μmol/L), acting on the GABA A receptor, and baclofen (1 μmol/L), acting on the GABA B receptor (Figure 4). According to previous data, both of these agonists showed a neuroprotective effect only when coapplied. (P<0.01 compared with control; n=4 for both).

Our data support the view that the neuroprotective effects of tiagabine, vigabatrin, and GABA itself are mediated by the activation of both GABA A and GABA B receptors. To further explore the potential role of presynaptic and/or postsynaptic mechanisms of action in the pharmacological neuroprotection of the striatum after ischemia, we used 2 GABA agonists: muscimol, a GABA A agonist, and baclofen, a GABA B agonist. These agonists showed a neuroprotective effect only when coapplied. Interestingly, we did not observe a linear relationship between the dose and the protective effect. In fact, for these drugs we obtained a bell-shaped dose-response curve. This finding may have different explanations. It is possible to speculate that high drug concentrations facilitate brain damage. It has been reported that endogenous GABA controls its own release via GABAergic autoreceptors. Thus, high levels of GABA mimic drugs reduce the release of endogenous GABA. Alternatively, it can be speculated that excessive activation of GABA B receptors may cause an overload of chloride ions into the neurons, leading to cell swelling.

The role of GABA in brain damage after energy deprivation has been investigated by using several experimental approaches. A number of studies demonstrated a neuroprotective role exerted by enhancing GABAergic transmission. Conversely, some in vitro studies found that GABA receptor agonists worsen the cerebral damage caused by energy deprivation.

Previous in vivo studies showed neuroprotective effects of GABA A and GABA B agonists given in isolation. Conversely, other studies either failed to show such neuroprotection or found relevant side effects associated with the administration of these agonists. Since our in vitro study clearly shows that coactivation of GABA A and GABA B receptors is required for GABA-mediated protection, future in vivo investigations should be performed to explore this issue further. It is possible that concomitant activation of both receptors would allow achievement of clinically relevant therapeutic effects even with low doses of agonists.
Acknowledgments

This study was supported by CNR and MIUR-Cofin grants to Drs Calabresi and Bernardi and by a Progetto Finalizzato Sanità grant to Dr Pisani. We wish to thank M. Tolu for technical assistance.

References

Coactivation of GABA_A and GABA_B Receptor Results in Neuroprotection During In Vitro Ischemia

Cinzia Costa, Giorgia Leone, Emilia Saulle, Francesco Pisani, Giorgio Bernardi and Paolo Calabresi

Stroke. 2004;35:596-600; originally published online January 15, 2004;
doi: 10.1161/01.STR.0000113691.32026.06

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/35/2/596

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/